



Weekly COVID-19 Evidence Review – August 3, 2021

Version 63

Contents

Contents..... 1

1. New Evidence Reviews and Findings..... 2

 PHAC ESG: Living Summary of SARS-CoV-2 Variants of Concern: The Delta variant profile - update 2

 PHAC ESG: Living Summary of SARS-CoV-2 Variants of Concern: The Gamma variant profile - update..... 3

 MHF: Factors affecting COVID-19 vaccination acceptance and uptake among the general public: a living behavioural science evidence synthesis (Version 4) 4

 MHF: Public Health Implications of SARS-CoV-2 VOC..... 5

 MHF: Evidence Spotlights 6

2. Previous PHAC Reviews..... 6

3. Previous non-PHAC Reviews..... 12

Page 002 of 149 to/à Page 017 of 149

Withheld pursuant to/removed as

Copyright



Weekly COVID-19 Evidence Review – August 9, 2021

Version 64

Contents

Contents.....	1
1. New Evidence Reviews and Findings	2
PHAC ESG: Living Summary of SARS-CoV-2 Variants of Concern: The Alpha Variant (B.1.1.7) profile.....	Error! Bookmark not defined.
PHAC ESG: Living Summary of SARS-CoV-2 Variants of Concern: The Beta Variant (B.1.351) profile.....	3
NCCMT: Living Rapid Review Update 17: What is the specific role of daycares and schools in COVID-19 transmission?.....	4
NCCMT: Living Rapid Review Update 3: What is known about the risk of transmission of COVID-19 within post-secondary institutions and the strategies to mitigate on-campus outbreaks?..	5
MHF: What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? (Version 15).....	6
MHF: Evidence Spotlights	7
2. Previous PHAC Reviews.....	8
3. Previous non-PHAC Reviews	14

Page 019 of 149 to/à Page 036 of 149

Withheld pursuant to/removed as

Copyright

Weekly COVID-19 Evidence Review – August 16, 2021

Version 65

Contents

Contents..... 1

1. New Evidence Reviews and Findings..... 2

PHAC ESG: Evidence Brief of SARS-CoV-2 Incubation Periods..... 2

PHAC ESG: Evergreen Rapid Review on COVID-19 Vaccine Attitudes and Uptake in Canada – Update 9 3

PHAC ESG: Living Summary of SARS-CoV-2 Variants of Interest: The C.37 (Lambda) Variant Profile, Highlights up to August 10, 2021 4

PHAC ESG: VOC Comparison Table of Alpha, Beta, Gamma and Delta..... 4

MHF: What went well and what could have gone better in the COVID-19 response in Canada, as well as what will need to go well in future given any available foresight work being conducted? (Version 4) 5

MHF: What went well and what could have gone better in the COVID-19 response in other countries, as well as what will need to go well in future given any available foresight work being conducted? (Version 3) 5

MHF: What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? (Version 16)..... 6

2. Previous PHAC Reviews..... 7

3. Previous non-PHAC Reviews..... 13

Page 038 of 149 to/à Page 054 of 149

Withheld pursuant to/removed as

Copyright



Weekly COVID-19 Evidence Review – August 23, 2021

Version 66

Contents

- 1. New Evidence Reviews and Findings** 2
 - MHF: What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? 2
 - MHF/SPOR EA: Canadian provincial and territorial public health response to SARS-CoV-2 and variants of concern: A jurisdictional scan including select European countries..... 3
 - MHF: Evidence Spotlights 4
- 2. Previous PHAC Reviews**..... 5
- 3. Previous non-PHAC Reviews** 11

Page 056 of 149 to/à Page 070 of 149

Withheld pursuant to/removed as

Copyright



Weekly COVID-19 Evidence Review – August 30, 2021

Version 67

Contents

- 1. New Evidence Reviews and Findings** 2
 - MHF/OHRI: Factors affecting COVID-19 vaccination acceptance and uptake among the general public: a living behavioural science evidence synthesis (Version 5) 2
 - MHF: What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? 3
- 2. Previous PHAC Reviews**..... 4
- 3. Previous non-PHAC Reviews** 10

Page 072 of 149 to/à Page 085 of 149

Withheld pursuant to/removed as

Copyright



Weekly COVID-19 Evidence Review – September 13, 2021

Version 69

Contents

1. New Evidence Reviews and Findings 2

PHAC ESG: Protective Immunity, Update 2 2

MHF: Evidence Spotlights 3

2. Previous PHAC Reviews..... 4

3. Previous External Reviews 10

Page 087 of 149 to/à Page 100 of 149

Withheld pursuant to/removed as

Copyright

Weekly COVID-19 Evidence Review – September 20, 2021

Version 70

Contents

1. New Evidence Reviews and Findings

PHAC ESG: Evidence on the Virulence, Transmission and Impact of B.1.617.2 (Delta) among Children

MHF: What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? (Version 20)

MHF: What is known about how schools (K-12) and post-secondary institutions (colleges and universities) adjust COVID-19 transmission-mitigation measures as infection rates change and vaccination rates increase? (Version 3)

SPOR Evidence Alliance/COVID-END: Public Health Implications of SARS-CoV-2 Variants of Concern

2. Previous PHAC Reviews

3. Previous External Reviews

2

2

3

4

4

5

12

Page 102 of 149 to/à Page 117 of 149

Withheld pursuant to/removed as

Copyright

Weekly COVID-19 Evidence Review – September 27, 2021

Version 71

Contents

Contents..... 1

1. New Evidence Reviews and Findings..... 2

OHRI/COVID-END: Factors affecting COVID-19 vaccination in Black communities in Canada: a behavioural analysis 2

OHRI/COVID-END: Factors affecting COVID-19 vaccination among people experiencing homelessness and precarious housing in Canada: a behavioural analysis..... 3

MHF: Evidence Spotlights 4

2. Previous PHAC Reviews..... 4

3. Previous External Reviews 10

Page 119 of 149 to/à Page 132 of 149

Withheld pursuant to/removed as

Copyright

Weekly COVID-19 Evidence Review – October 18, 2021

Version 74

Contents

Contents..... 1

1. New Evidence Reviews and Findings..... 2

PHAC ESG: Evergreen Rapid Review on COVID-19 Vaccine Attitudes and Uptake in Canada, Update 11 2

PHAC ESG: Evidence on the Virulence, Transmission and Impact of B.1.617.2 (Delta) among Children, Update 1 3

NCCMT: Rapid Review Update 1: What is the ongoing effectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed COVID-19 infection?..... 4

MHF: What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? (Version 22)..... 5

2. Previous PHAC Reviews..... 6

3. Previous External Reviews 12

Page 134 of 149 to/à Page 149 of 149

Withheld pursuant to/removal as

Copyright